When should clinicians report adverse events to FDA MedWatch, and what information should be included?

• A. For suspected serious or unexpected ADRs or medication errors; include patient data.
• B. For suspected unrelated events, with patient data only.
• C. For any minor adverse event, with minimal data.
• D. For suspected serious or unexpected ADRs or medication errors; include patient data, suspected drug, event details, and outcomes.

Answer: (D)

Reporting to MedWatch is for suspected serious or unexpected adverse drug reactions or medication errors. To be useful for safety assessment, the report should include complete information: patient data (age, sex, relevant identifiers), the suspected drug, details of the adverse event (what happened, symptoms, onset, severity), and the outcome (recovery, ongoing symptoms, hospitalization, disability, death). Including these elements helps FDA evaluate causality and detect safety signals across the population. Minor events are not the focus for mandatory reporting, and events that are clearly unrelated are not routinely reported. So the best approach is to provide a report that covers patient data, the suspected drug, event details, and outcomes for serious or unexpected ADRs or medication errors.